CN111388523A - 一种治疗痤疮的制剂及其制备方法 - Google Patents
一种治疗痤疮的制剂及其制备方法 Download PDFInfo
- Publication number
- CN111388523A CN111388523A CN202010294540.0A CN202010294540A CN111388523A CN 111388523 A CN111388523 A CN 111388523A CN 202010294540 A CN202010294540 A CN 202010294540A CN 111388523 A CN111388523 A CN 111388523A
- Authority
- CN
- China
- Prior art keywords
- preparation
- menthol
- treating acne
- radix sophorae
- acne
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010000496 acne Diseases 0.000 title claims abstract description 24
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940041616 menthol Drugs 0.000 claims abstract description 14
- 239000004372 Polyvinyl alcohol Substances 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 12
- 229920002451 polyvinyl alcohol Polymers 0.000 claims abstract description 12
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 11
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 14
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 12
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 12
- 238000003756 stirring Methods 0.000 claims description 12
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 9
- 229940116229 borneol Drugs 0.000 claims description 9
- 241000246044 Sophora flavescens Species 0.000 claims description 6
- 239000013078 crystal Substances 0.000 claims description 4
- 238000011049 filling Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 238000000227 grinding Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims 2
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 4
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 13
- 206010061218 Inflammation Diseases 0.000 description 6
- 210000003491 skin Anatomy 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 5
- DTGKSKDOIYIVQL-MRTMQBJTSA-N Isoborneol Natural products C1C[C@@]2(C)[C@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-MRTMQBJTSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000004429 Bacillary Dysentery Diseases 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000223935 Cryptosporidium Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 201000006353 Filariasis Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 201000005113 shigellosis Diseases 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- XVPBINOPNYFXID-JARXUMMXSA-N 85u4c366qs Chemical compound C([C@@H]1CCC[N@+]2(CCC[C@H]3[C@@H]21)[O-])N1[C@@H]3CCCC1=O XVPBINOPNYFXID-JARXUMMXSA-N 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 240000000572 Blumea balsamifera Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010009168 Chyluria Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 241000224467 Giardia intestinalis Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- NYGZYUAVZPIKBZ-BDJLRTHQSA-N Kushenin Natural products O(C)c1c(O)cc2O[C@H]3[C@@H](c2c1)COc1c3ccc(O)c1 NYGZYUAVZPIKBZ-BDJLRTHQSA-N 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- NYGZYUAVZPIKBZ-UHFFFAOYSA-N Lespedezol D1 Natural products C1OC2=CC(O)=CC=C2C2C1C(C=C(C(=C1)O)OC)=C1O2 NYGZYUAVZPIKBZ-UHFFFAOYSA-N 0.000 description 1
- 244000245214 Mentha canadensis Species 0.000 description 1
- 235000001878 Mentha haplocalyx Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010037888 Rash pustular Diseases 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000779819 Syncarpia glomulifera Species 0.000 description 1
- 241001502500 Trichomonadida Species 0.000 description 1
- 241000224527 Trichomonas vaginalis Species 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- 241001480046 Trichophyton schoenleinii Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229960002255 azelaic acid Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960003328 benzoyl peroxide Drugs 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 229940085435 giardia lamblia Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- NYGZYUAVZPIKBZ-ZBEGNZNMSA-N lespedezol D1 Chemical compound C1OC2=CC(O)=CC=C2[C@H]2[C@@H]1C(C=C(C(=C1)O)OC)=C1O2 NYGZYUAVZPIKBZ-ZBEGNZNMSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229930015582 oxymatrine Natural products 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000001739 pinus spp. Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 208000029561 pustule Diseases 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 229960005349 sulfur Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940036248 turpentine Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
本发明提供的一种治疗痤疮的制剂。所述治疗痤疮的是由苦参提取物2‑20g、冰片0.1‑0.5 g、薄荷醇0.1‑0.5g、甘油10‑30g、聚乙烯醇0.5‑80 g、纯水至1000ml制成。本制剂对皮肤有抑菌抗炎作用，达到治疗痤疮护肤的良好效果。
Description
技术领域
本发明涉及卫生保健护理技术领域，具体涉及一种治疗痤疮的制剂及其制备方法。
背景技术
痤疮是一种与分泌功能失调有关的毛囊 、皮脂腺慢性炎症性皮肤病 。皮脂腺多开口于毛囊口，一旦毛囊口阻塞，过多的皮脂代谢产生的过多的脂肪酸的刺激以及封闭环境中过度增殖的痤疮丙酸杆菌的作用，使皮肤产生了炎症反应，因此痘痘的表现从轻到重是白头黑头粉刺、炎性丘疹和脓疱、囊肿和结节， 而发红和化脓的痘痘是有细菌感染存在的。
常用治疗方法有：口服抗生素、维A酸类或雌激素、糖皮质激素药物对抗治疗，局部使用维A酸类、过氧化苯甲酰、抗生素类、壬二酸、硫磺洗剂等。
但人们仍然在探索和研究更新、更有效的产品，使其能够对治疗痤疮产生作用，为痤疮患者服务。
发明内容
本发明旨在提供一种治疗痤疮的制剂，外用涂抹，治疗痤疮，健康肤质。
本发明的又一目的是提供上述治疗痤疮的制剂的制法，使其能够批量生产。
本发明提供的一种治疗痤疮的制剂是由以下几种物质及比例组成：苦参提取物2-20g、冰片0.1-0.5g、薄荷脑0.1-0.5g、甘油10-30g、聚乙烯醇0.5-80g、纯水加至1000ml。
本发明制剂中苦参提取物以苦参总生物碱计量。
本发明提供一种治疗痤疮的制剂其制备方法：
（1）将聚乙烯醇加入500ml水中加热搅拌溶解后加入苦参提取物搅拌95℃1小时；
（2）冰片与薄荷脑研磨溶解后加入甘油混匀后加入（1）溶液中，加水至1000ml搅拌均匀，滤过，灌装，包装，检验，即得。
上述配方中，苦参为豆科多年生落叶亚灌木植物苦参(Sophoratlaveseens Ait．)的干燥根．又名苦甘草、苦参草、苦豆根、西豆根、苦平子、野槐根、山槐根、干人参、苦骨等。苦参性苦、寒。具清热燥湿、杀虫、利尿等功效；用于热痢，便血。黄疸尿闭，赤白带下。阴肿阴痒。药理试验和临床观察证明（1）抗寄生虫作用．苦参能抑制或杀灭蓝氏贾第鞭毛虫和阿米巴原虫．在体外其醇浸膏有抗滴虫作用。以苦参为主的复方制剂在治疗血丝虫病引起的乳糜尿方面效果显效．表明了苦参有抗血丝虫的作用。（2）抗菌作用苦参对痢疾杆菌、大肠杆菌、变形杆菌、金黄色葡萄球菌和乙型链球菌均有明显抑制作用。对结核杆菌和皮肤致病性真菌也有不同程度的抑制作用。而且作为一种中药抗菌药毒副作用小，治疗效果好，不易产生耐药性。苦参对瘙痒性皮肤病及细菌、真菌(如毛癣菌、黄癣菌、红色表皮癣菌、糠秕孢子菌)、昆虫、原虫(如贾第虫病)所致的皮肤病疗效显著。现代药理研究证实，8％一35％苦参煎汁对许兰氏癣菌、白色念珠菌等多种真菌有抗菌作用．并可杀灭阴道滴虫。苦参还可用于治疗慢性结肠炎、滴虫性肠炎、急性肠胃炎、细菌性痢疾、慢性迁延性菌痢。D毛乓对目前尚无特效治疗药的隐孢子虫(CryptosporidiumcPS)感染具有有一定的疗效。（3）抗炎、抗过敏和抗平喘 苦参素对多种致炎剂诱发的动物炎症有抵抗作用。郑萍等陶发现氧化苦参碱可降低ICAM—l(细胞间粘附分子一1)表达。使其与白细胞的相互作用减弱从而减轻炎症活动性。同时降低NF—KB活性．阻断炎症的关键启始步骤及其次级炎症。张琪I=Sl发现氧化苦参碱对过敏反应有不同程度的抑制作用．机制在于抑制IgE及其特异性抗原引起的肥大细胞组胺释放。
冰片是由菊科艾纳香茎叶或樟科植物龙脑樟枝叶经水蒸汽蒸馏并重结晶而得。亦有用松节油经一系列化学方法工艺而得。现代药理研究，冰片具有. 抑菌、抗炎作用体外实验表明： 较高浓度的冰片（0.5%）有抑菌作用．合成冰片和天然冰片的抑菌作用相同．龙脑、异龙脑均有抗菌作用；并均能显著抑制大鼠蛋清性足跖肿胀；异龙脑对巴豆油耳廓肿胀亦有抑制作用．提示它们对液体的渗出和组织水肿等炎肿过程有抑制作用。
薄荷脑是唇形科植物薄荷Mentho haplocalyx Bing)全草中提取的高挥发性精油，其成份多为半萜、单萜及倍半萜，有止痒、止痛、防腐、刺激、麻醉、清凉和抗炎作用。
聚乙烯醇、药用级聚乙烯醇是一种极安全的高分子有机物，对人体无毒，无副作用，具有良好的生物相容性，尤其在医疗中的如其水性凝胶在眼科、伤口敷料和人工关节方面的有广泛应用，同时在聚乙烯醇薄膜在药用膜，人工肾膜等方面也有使用。其安全性可以用于伤口皮肤修复。
本发明的治疗痤疮的制剂通过组方中的各种成分，合理量搭配，取到对皮肤的抑菌抗炎作用，达到治疗痤疮护肤的良好效果。
具体实施方式
实施例1
优选的，本发明治疗痤疮的制剂的一种实施例，所述制剂为：苦参提取物2g、冰片0.3 g、薄荷脑0.2g、甘油15g、聚乙烯醇20g、纯水至1000ml 。
本发明提供所述制剂其制备方法：
（1）将聚乙烯醇加入500ml水中加热搅拌溶解后加入苦参提取物搅拌95℃1小时；
（2）冰片与薄荷脑研磨溶解后加入甘油混匀后加入（1）溶液中，加水至1000ml搅拌均匀，滤过，灌装，包装，检验，即得。
实施例2
优选的，本发明治疗痤疮的制剂的一种实施例，所述制剂为：苦参提取物20g、冰片0.5g 、薄荷脑0.5g、甘油30g、聚乙烯醇80 g、纯水至1000ml
本发明提供所述制剂其制备方法：
（1）将聚乙烯醇加入500ml水中加热搅拌溶解后加入苦参提取物搅拌95℃1小时；
（2）冰片与薄荷脑研磨溶解后加入甘油混匀后加入（1）溶液中，加水至1000ml搅拌均匀，滤过，灌装，包装，检验，即得。
以上内容是结合具体的优选实施方式对本发明所作的进一步详细说明，不能认定本发明的具体实施只局限于这些说明。对于本发明所属技术领域的普通技术人员来说，在不脱离本发明构思的前提下做出若干替代或明显变型，而且性能或用途相同，都应当视为属于本发明的保护范围。
Claims (4)
1.一种治疗痤疮的制剂，其特征在于，包括以下原料：苦参提取物、冰片、薄荷醇、甘油、、聚乙烯醇、纯水。
2.根据权利要求1所述的治疗痤疮的制剂，其特征在于，包括如下重量份数的原料：苦参提取物2-20g、冰片0.1-0.5 g 、薄荷醇0.1-0.5g、甘油10-30g、聚乙烯醇0.5-80 g、纯水至1000ml。
3.权利要求1-2的.一种治疗痤疮的制剂的制备方法，包括如下步骤：
（1）将聚乙烯醇加入500ml水中加热搅拌溶解后加入苦参提取物搅拌95℃1小时；
（2）冰片与薄荷脑研磨溶解后加入甘油混匀后加入（1）溶液中，加水至1000ml搅拌均匀，滤过，灌装，包装，检验，即得。
4.根据权利要求1所述.一种治疗痤疮的制剂，其特征是，用于治疗皮肤痤疮。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010294540.0A CN111388523A (zh) | 2020-04-15 | 2020-04-15 | 一种治疗痤疮的制剂及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010294540.0A CN111388523A (zh) | 2020-04-15 | 2020-04-15 | 一种治疗痤疮的制剂及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111388523A true CN111388523A (zh) | 2020-07-10 |
Family
ID=71411378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010294540.0A Pending CN111388523A (zh) | 2020-04-15 | 2020-04-15 | 一种治疗痤疮的制剂及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111388523A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116327874A (zh) * | 2021-12-23 | 2023-06-27 | 海南碧凯药业有限公司 | 用于治疗痤疮的药物组合物及外用制剂及其制备方法 |
-
2020
- 2020-04-15 CN CN202010294540.0A patent/CN111388523A/zh active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116327874A (zh) * | 2021-12-23 | 2023-06-27 | 海南碧凯药业有限公司 | 用于治疗痤疮的药物组合物及外用制剂及其制备方法 |
| CN116327874B (zh) * | 2021-12-23 | 2024-02-13 | 海南碧凯药业有限公司 | 用于治疗痤疮的药物组合物及外用制剂及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103721131B (zh) | 一种治疗妇女慢性盆腔炎的中药栓剂及其制备方法 | |
| CN103110868B (zh) | 一种皮肤护理液及其制备方法 | |
| CN113081928B (zh) | 一种植物抑菌凝胶及其制备方法和应用 | |
| WO2006076844A1 (fr) | Medicament chinois traditionnel destine a traiter les blessures resultant de chutes, rhumatisme et ostealgie et son procede de fabrication | |
| CN102205026A (zh) | 一种治疗小儿慢性鼻窦炎的中药组合物及其制备方法 | |
| CN102038975A (zh) | 中草药植物液棉纱布卫生巾 | |
| CN105232725A (zh) | 一种祛痘配方及其制备方法 | |
| WO2014059880A1 (zh) | 一种制备治疗妇科炎症的石榴皮多酚凝胶剂的方法 | |
| CN102872241A (zh) | 一种用于治疗炎症性皮肤病的中药组合物及其制剂 | |
| CN111388523A (zh) | 一种治疗痤疮的制剂及其制备方法 | |
| CN106822321B (zh) | 伤科黄水在制备治疗毛周角化症的药物中的应用 | |
| CN101361950A (zh) | 一种具有活血、散瘀、止痛等保健功效的妇科中药及其制备方法 | |
| CN110051719B (zh) | 一种透骨草和侧柏叶混合提取物及其提取工艺与应用 | |
| CN108785212B (zh) | 一种具有抑菌和抗螨的中药复合物及其应用 | |
| CN109453327B (zh) | 一种具有祛痘功效的中药组合物及其水提物和发酵物以及应用 | |
| CN107149641B (zh) | 一种用于治疗烧烫伤的组合物 | |
| CN112294929A (zh) | 一种妇科中药盐洗液及其制备方法和应用 | |
| CN111358851A (zh) | 一种用于治疗宠物皮肤病的凝胶剂及其制备方法 | |
| CN101766731B (zh) | 茶多酚抗痤疮外用制剂 | |
| CN111184832A (zh) | 一种具有缩阴润滑、养巢护巢功能的植物益生菌组合物及其制备方法 | |
| CN111658586A (zh) | 一种具有除螨祛痘的中药组合物及其制备方法和应用 | |
| Randive et al. | Burn wound healing activity of kyuhr herbal cream-a case report | |
| CN107854542A (zh) | 一种治疗内外痔疮的中药制剂及其制备方法 | |
| CN113230293B (zh) | 一种消风败毒的中药组合物及其制备方法 | |
| RU2782695C1 (ru) | Состав для наружного применения "септисол" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200710 |
|
| WD01 | Invention patent application deemed withdrawn after publication |